ProShares Ultra NASDAQ Biotechnology
BIB
31 hedge funds and large institutions have $19.8M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 11 closing their positions.
4.88% more ownership
Funds ownership: 0% → 4.88% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 35 → 31 (-4)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
31% less capital invested
Capital invested by funds: $28.7M → $19.8M (-$8.93M)
32% less call options, than puts
Call options by funds: $6.49M | Put options by funds: $9.59M
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$498K |
| 2 |
Morgan Stanley
New York
|
+$472K |
| 3 |
HF
HRT Financial
New York
|
+$442K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$416K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$294K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.97M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.22M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$1.07M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$831K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$790K |
BIB Hedge Fund Activity: Q4 2016 in Review
31 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2016, worth a combined $19.8M — down 31% from $28.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BIB and 8 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $498K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.97M sold.
- 31 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2016, down from 35 in Q3 2016.
- Funds reported $19.8M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2016, down 31% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2016 and 11 closed out, a net change of -3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2016 was Virtu KCG Holdings, an estimated $498K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2016 was Susquehanna International Group, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2016.